Cyclo-oxygenase 2 inhibitor, nabumetone, inhibits proliferation in chronic myeloid leukemia cell lines.

Vural F., Ozcan M., Ozsan G. H., Ateş H., Demirkan F., Piskin O., ...Daha Fazla

Leukemia & lymphoma, cilt.46, sa.5, ss.753-6, 2005 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 46 Sayı: 5
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1080/10428190400027860
  • Dergi Adı: Leukemia & lymphoma
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.753-6
  • Anahtar Kelimeler: cyclo-oxygenase, nabumetone, chronic myeloid leukemia, COLON-CANCER, MARROW-TRANSPLANTATION, CHRONIC-PHASE, EXPRESSION, APOPTOSIS, CHEMOPREVENTION, GENE, INDUCTION, CASPASES, ABL
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

The anti-tumor effect of cyclo-oxygenase (COX) inhibitors has been documented in several studies. COX2 inhibitors have attracted more attention because of the fewer side-effects and the more prominent anti-tumor effects. However, experience with these drugs in hematological malignancies is limited. In our study, a potent COX2 inhibitor, nabumetone (NBT), was investigated for its anti-proliferative and apoptotic effects in K-562 and Meg-01 chronic myeloid leukemia blastic cell lines as a single agent or in combination with adriamycin (ADR) and interferon alpha (IFN-alpha). In these cell lines, a dose-dependent inhibition of proliferation was observed with NBT. We observed no significant apoptotic effect of NBT. However, NBT potentiated the apoptotic effect of ADR in the K-562 cell line. Bcl-2 expression was reduced by NBT (11% vs. 2%). The combination of NBT with IFN did not have any significant effect on the K-562 cell line. We suggest that NBT inhibits proliferation and potentiates the apoptotic effect of ADR in chronic myeloid leukemia cell lines.